Eli Lilly and Company, currently riding an unprecedented wave of success fueled by its GLP-1 franchise, has announced its intent…
Read More
Fake testimonials, no pharmacy and an FDA warning: how Medvi built a $1.8 billion telehealth company in the gaps between regulators
The recent trajectory of Medvi, a telehealth company projected to achieve a staggering $1.8 billion valuation this year, casts a…
Read More
Gilead Sciences Finalizes $5 Billion Acquisition of Tubulis, Bolstering Oncology Pipeline with Advanced ADC Technology
Gilead Sciences has officially completed its acquisition of Tubulis, a prominent German biotechnology firm specializing in the development of next-generation…
Read More
CVC Capital Partners and Groupe Bruxelles Lambert Launch $12.4 Billion Takeover Bid for Recordati, Signaling Potential Shift to Private Ownership
One of Italy’s few remaining publicly traded large pharmaceutical companies, Recordati, is on the cusp of transitioning to private ownership…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
Over the past 16 months, Chinese-domiciled biotechnology companies have emerged as significant players in the global pharmaceutical landscape, securing approximately…
Read More
Billion Cell Atlas Unveiled: A New Horizon for AI-Driven Drug Discovery and Disease Understanding
In a landmark initiative poised to revolutionize pharmaceutical research, scientists have announced the launch of the Billion Cell Atlas, an…
Read More
Takeda Ordered to Pay $885 Million in Landmark "Pay-for-Delay" Drug Case, Faces Potential $2.5 Billion Liability
In a groundbreaking verdict that could reshape pharmaceutical antitrust litigation, a U.S. jury has found Japanese pharmaceutical giant Takeda liable…
Read More
Global Healthcare Giants Unite: GHO Capital and CBC Group Forge Largest Dedicated Investment Manager with $21 Billion AUM
Two prominent forces in specialized healthcare investment, Global Healthcare Opportunities (GHO) and CBC Group, have announced a groundbreaking merger to…
Read More
Regeneron Pharmaceuticals and Parabilis Medicines Forge Landmark $2.32 Billion Collaboration to Pioneer a New Era of Intracellular Therapies
Regeneron Pharmaceuticals has announced a monumental research collaboration with Parabilis Medicines, a deal valued at an impressive $2.32 billion. This…
Read More
Insilico CEO sees potentially $2.75 billion collaboration as ‘fusing Lilly’s clinical excellence’ with Insilico’s ‘end-to-end AI engine’
In a landmark move poised to reshape the landscape of pharmaceutical innovation, Insilico Medicine, a pioneer in artificial intelligence (AI)-driven…
Read More
